ABCL (AbCellera Biologics) Net Profit

ABCL (AbCellera Corp) - company brandmark

AbCellera Biologics (ABCL) operates a closed AI environment for antibody discovery, making a change of technological partners extremely costly for industry behemoths. The business's profitability relies on licensing fees from collaborations with pharma giants and the development of its own drugs. The price action on GURU.Markets, where the profit indicator is -0.16, is complemented by personnel stability, as the company successfully retains rare specialists at the intersection of bioinformatics and IT.

ABCL (AbCellera) Net Profit history from 07/04/2022 to 10/31/2026

Analytical breakdowns and data insights for company AbCellera Corp (ABCL)

- price and consensus price forecast:
Stock Quotes AbCellera Biologics Inc.|ABCL - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization AbCellera Bio|ABCL - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share AbCellera|ABCL - Book Capitalization|Market Capitalization to Book Value abcellera.com|ABCL - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio AbCellera Biologics|ABCL - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio AbCellera Bio|ABCL - Company Total Debt|Debts to Book Capitalization AbCellera Bio|ABCL - Company Long-Term Debt|Company Short-Term Indebtedness AbCellera|Immediate Liquidity abcellera.com
- net income and valuation multiples indicators:
ABCL - Net Profit
Summary company analysis:AbCellera Biologics
Core merchandise of AbCellera Biologics

This indicator measures the aggregate financial result by separating objective profitability from market growth expectations. Analyzing the company's actual profit allows for the diagnosis of hidden operational failures through local dips in the curve. The stability of the metric confirms the resilience of the business model and the fundamental health of the enterprise. For AbCellera Biologics (ABCL), this reflects the monetization efficiency of its unique microfluidic screening. The proprietary AI platform ensures profit protection from direct market competition.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit TRML (Tourmaline Bio)|Precigen Inc (PGEN) - Company Net Income|Pharming - Net Profit|NKTR - Net Profit|UPB: Net Profit|ZBIO (zenasbio.com) - Company Net Income|IMNM (Immunome) - Net Profit|Net Income Gossamer Bio Inc (GOSS)|Net Profit KALV|SEPN - Company Net Income|Company Net Income Pieris Pharmaceuticals PVLA|savarapharma.com - Company Net Income|RIGL - Company Net Income|ANAB: Company Net Income|ATXS: Net Profit|Company Net Income enGene Corp (ENGN)|Company Net Income RAPT Therapeutics, Inc.|JBIO: Final Profit|Net Profit ACRS|Net Profit Kyverna Therapeutics Inc. (KYTX)|Tiziana Life Sciences PLC - Net Income|Final Profit CABA|Ventyx Biosciences - Net Profit|THTX: Company Net Income|AVTX: Net Profit|ELDN - Net Financial Result|Company Net Income Agenus Inc|Company Net Income Climb Bio, Inc CLYM|Company Net Income Zura Bio Limited (ZURA)|Company Net Income ATYR (atyrpharma.com)|Company Net Income Adagene Inc. ADAG|ImageneBio (IMA) - Company Net Income|Shattuck Therapeutics - Net Profit|Annual Net Income Equillium, Inc. (EQ)|CNTB: Net Profit|IMUX - Net Financial Result|ATRA (Atara Biotherapeutics, Inc.) - Net Profit|Net Income InflaRx GmbH (IFRX)|Company Net Income X4 Pharma (XFOR)|Net Financial Result adicetbio.com|Net Profit CELU (Celularity)|Net Profit inmunebio.com INMB|Barinthus Biotherapeutics plc - Net Profit|KZR: Company Net Income|SABS: Net Profit|Net Income Akari Therapeutics, Plc|Company Net Income Enlivex Therapeutics Ltd|Company Net Income QTTB|Company Net Income GeoVax (GOVX)|EDSA: Profit After Tax|Net Profit IBIO (iBio Corp)|Final Profit CARM|XTL Biopharmaceuticals - Net Profit|BOLT - Net Profit|hcwbiologics.com (HCWB) - Company Net Income|Aptevo Therapeutics Inc. - Final Profit|Company Net Income AIM ImmunoTech|Net Income Aditxt Corp (ADTX)|Net Profit GRI|Net Profit xortx.com (XRTX)|Vyome Holdings - Net Income|Final Profit REVB|Indaptus - Net Profit|Net Financial Result BiondVax Pharmaceuticals SCNI|calcimedica.com (CALI) - Company Net Income|Net Income Affimed N.V.|Company Net Income Allakos Inc|Net Income HOOKIPA (HOOK)|Net Income IGMS (IGM Biosciences, Inc.)|Net Profit iTeos Pharma (ITOS)|Company Net Income Ocean Biomedical, Inc. OCEA|TCBP: Company Profit|Third Harmonic Bio, Inc. - Net Profit